sibutramine has been researched along with Fatty Liver in 4 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 9.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 5.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "Sibutramine is widely used as a weight-loss substance in the treatment of obesity and is a selective inhibitor of the neuronal reuptake of serotonin and noradrenaline." | 3.79 | Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis. ( Bester, MJ; Oberholzer, HM; van der Schoor, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oberholzer, HM | 1 |
| Bester, MJ | 1 |
| van der Schoor, C | 1 |
| Sabuncu, T | 1 |
| Nazligul, Y | 1 |
| Karaoglanoglu, M | 1 |
| Ucar, E | 1 |
| Kilic, FB | 1 |
| Clark, JM | 1 |
| Dalmau Serra, J | 1 |
| Alonso Franch, M | 1 |
| Gómez López, L | 1 |
| Martínez Costa, C | 1 |
| Sierra Salinas, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease[NCT03354247] | 100 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for sibutramine and Fatty Liver
| Article | Year |
|---|---|
Weight loss as a treatment for nonalcoholic fatty liver disease.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Chronic Disease; Cyclobutanes; Diet, R | 2006 |
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy | 2007 |
1 trial available for sibutramine and Fatty Liver
| Article | Year |
|---|---|
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Fatty Liver; Fema | 2003 |
1 other study available for sibutramine and Fatty Liver
| Article | Year |
|---|---|
Rats on a high-energy diet showing no weight gain present with ultrastructural changes associated with liver fibrosis.
Topics: Animals; Appetite Depressants; Body Mass Index; Cyclobutanes; Diet, High-Fat; Disease Models, Animal | 2013 |